Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial.

Department of Medicine, University of California, Los Angeles, California 90095, USA.
The American Journal of Gastroenterology (Impact Factor: 9.21). 01/2011; 106(1):71-7. DOI: 10.1038/ajg.2010.299
Source: PubMed

ABSTRACT Nonalcoholic fatty liver disease (NAFLD) is defined as the spectrum of benign fatty liver to necroinflammation and fibrosis. Its prevalence has been found to be as high as 39%. It is estimated that up to 15% of those affected will go on to have progressive liver disease. Currently, there is no proven therapy for NAFLD. In this study, we aim to determine whether statin therapy may be an effective treatment for NAFLD and identify independent predictors of NAFLD.
In all, 1,005 men and women, aged 50-70 years were randomized to receive either a daily combination of atorvastatin 20 mg, vitamin C 1 g, and vitamin E 1,000 IU vs. matching placebo, as part of the St Francis Heart Study randomized clinical trial. Liver to spleen (LS) ratios were calculated on 455 subjects with available computed tomography scans performed at baseline and follow-up to determine NAFLD prevalence. Baseline and final LS ratios were compared within treatment groups, and results were compared between the treatment and placebo groups using univariate and multivariate analyses. Mean duration of follow-up was 3.6 years.
There were 80 patients with NAFLD at baseline. We identified baseline triglyceride levels (odds ratio (OR)=1.003, P<0.001) and body mass index (OR=0.10, P<0.001) as independent correlates of NAFLD. Treatment with atorvastatin combined with vitamins E and C significantly reduced the odds of NAFLD at the end of follow-up, 70 vs. 34% (OR=0.29, P<0.001).
In conclusion, atorvastatin 20 mg combined with vitamins C and E is effective in reducing the odds of having hepatic steatosis by 71% in healthy individuals with NAFLD at baseline after 4 years of active therapy.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Non-alcoholic steatohepatitis (NASH), an under-recognized hepatic ailment with increasing prevalence, is fast emerging as the dark horse of hepatic related morbidity and mortality. Though introduced as a hepatic condition as early as 1980, detailed exploration of its causes, underlying mechanisms and therapeutics has largely remained an ignored or neglected field. Only recently, the focus of attention has gravitated towards an understanding of NASH as a pathological manifestation of significance and a search for possible therapeutic interventions. Treatment schedules as of now involve life style management and usage of anti-diabetic or anti-obesity drugs and antioxidants. In the present review, we have focused on the available treatment schedules including herbal agents, plant extracts, polyherbal formulations and isolated phytocompounds. We present here a review of the available literature on pre-clinical and clinical evaluations of herbals including our recent findings on two plant extracts which can be used in mitigating NASH. This review attempts to provide a comprehensive account of NASH and the future of therapeutics and remediation by herbal principles, an aspect of the urgent need to target this important medical condition that contributes to many cases of silent morbidity and mortality.
    Journal of applied biomedicine 01/2012; 10(3). · 1.78 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Obesity and the subsequent reprogramming of the white adipose tissue are linked to human disease-complexes including metabolic syndrome and concurrent non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The dietary imposed dyslipidemia promotes redox imbalance by the generation of excess levels of reactive oxygen species and induces adipocyte dysfunction and reprogramming, leading to a low grade systemic inflammation and ectopic lipid deposition, e.g., in the liver, hereby promoting a vicious circle in which dietary factors initiate a metabolic change that further exacerbates the negative consequences of an adverse life-style. Large epidemiological studies and findings from controlled in vivo animal studies have provided evidence supporting an association between poor vitamin C (VitC) status and propagation of life-style associated diseases. In addition, overweight per se has been shown to result in reduced plasma VitC, and the distribution of body fat in obesity has been shown to have an inverse relationship with VitC plasma levels. Recently, a number of epidemiological studies have indicated a VitC intake below the recommended daily allowance (RDA) in NAFLD-patients, suggesting an association between dietary habits, disease and VitC deficiency. In the general population, VitC deficiency (defined as a plasma concentration below 23 μM) affects around 10% of adults, however, this prevalence is increased by an adverse life-style, deficiency potentially playing a broader role in disease progression in specific subgroups. This review discusses the currently available data from human surveys and experimental models in search of a putative role of VitC deficiency in the development of NAFLD and NASH.
    Nutrients 12/2014; 6(12):5473-5499. · 3.15 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We read with interest the recent article by Malaguarnera et al. (1) on the reduction of non-alcoholic fatty liver disease (NAFLD) in patients receiving treatment for hepatitis C who were also treated with rosuvastatin. According to the results presented in the study, patients in the group receiving interferon, ribavirin, and rosuvastatin showed major improvements in their levels of aminotransferase, fasting glucose, insulin, and CRP and their HOMA index. Apparently, these parameters were predictors of sustained virological response (SVR) in the univariate analysis, but not in the multivariate analysis. We believe that the design of the clinical trial was adequate to eliminate potential confounding factors. Both groups were similar, and the liver tissue collected both before and after treatment allowed for an objective evaluation of steatosis in these patients. The results found by the authors seem to be promising; however, it is clear that the main weakness of the study is that it was conducted in patients who received antiviral treatment, leukocyte interferon alpha, which is not the standard of care for hepatitis C. At the same time, it is striking that these patients achieved such a high rate of SVR, one similar to those treated with the current combination therapy of peginterferon (Peg-INF) plus ribavirin. This could be explained because the authors analyzed the two groups (with and without rosuvastatin) without separating the patients by genotype, which is the most important factor for SVR. Currently, most studies prefer to investigate new therapies only in genotype 1 patients because they are the most difficult to treat. Another limitation one has to consider with regard to the study is that the sample size was not adequate to obtain enough power to detect a statistically significant difference. Several studies suggest that lipid-lowering agents, i.e., inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, also known as statins, may have a potential therapeutic effect on hepatitis C. These agents could block the formation of lipid precursors by interfering with viral replication, but results of in vitro and clinical studies have yielded conflicting results. Forde et al. (2) conducted a longitudinal cross-sectional study investigating the effect on viral loads in 101 patients with hepatitis C who received statins. They did not find a significant change in viral replication (HCV RNA-titers) before and after treatment with statins.


Available from